The DP2 receptor pathway has been heralded as a novel and important therapeutic target for asthma. We sat down with Dr David Sandham, from the Novartis Institutes for Biomedical Research in Cambridge, to share the back story on targeting DP2. Dr Sandham was in Australia for the TSANZSRS 2019 Annual Scientific Meeting on the Gold Coast. Why is ...
The DP2 pathway: a promising target for new asthma therapies?
Sponsored by Novartis Pharmaceuticals Australia Pty Ltd
22 May 2019